Business Context and Reporting Period
This Form 8-K Current Report was filed by Galectin Therapeutics Inc. on October 11, 2011, covering events occurring on September 30, 2011, and October 11-12, 2011. The company is a Nevada corporation headquartered in Newton, Massachusetts.
Key Financial Metrics
- Cash Position: Approximately $8.0 million as of September 30, 2011.
- Capital Raised: Gross proceeds of $1,205,000 received on September 30, 2011, from the exercise of Series A-1 Warrants by 10X Fund L.P.
- Shares Issued: 2,410,000 shares of common stock issued upon warrant exercise.
- Revenue/Profit/Margins: The filing text does not provide a clear value for revenue, profit, cash flow, or margins.
- Debt: The filing text does not provide a clear value for outstanding debt.
Material Changes
- Board Composition: Dr. Marc Rubin was appointed to the Board of Directors on October 12, 2011, filling a vacancy created by the resignation of S. Colin Neill effective October 11, 2011.
- Liquidity Event: The company received $1.205 million in cash from the full exercise of remaining Series A-1 Warrants held by 10X Fund L.P.
Management Commentary, Risks, and Unusual Items
- Compensatory Arrangements: Dr. Rubin's appointment includes two years of annual compensation valued at $60,000 per year ($12,000 cash and $48,000 in stock options). The options cover 98,970 shares at an exercise price of $0.97 per share, vesting over eight quarterly installments.
- Management Background: Dr. Rubin brings significant experience, having served as President and CEO of Titan Pharmaceuticals Inc. and previously held executive roles at Bayer Schering Pharma and GlaxoSmithKline.
- Risks/Contingencies: The filing text does not provide a clear value for specific risks or contingencies beyond standard corporate governance changes.
Investor Verification Checklist
- Verify the impact of the $1.205 million cash infusion on the company's runway and operational timeline.
- Confirm the vesting schedule and dilution impact of the 98,970 stock options granted to Dr. Rubin.
- Review the strategic rationale for appointing Dr. Rubin given his background in oncology and infectious diseases.
- Check subsequent filings for any changes to the $8.0 million cash position reported as of September 30, 2011.